logo-loader
Arix Bioscience PLC

Arix Biosciences boost after investee company floats on NASDAQ

The UK investor in life sciences opportunities owns a stake 12.9% stake in LogicBio

human genome
The US research and development group has licensed technology from Stanford and Texas universities that allows the insertion of corrective genes to the human genome

Arix Biosciences PLC (LON:ARIX) has seen a significant uplift in the value of its investment in a pre-clinical genome editing company, which recently made its stock market debut on NASDAQ.

The UK investor in life sciences opportunities owns a stake 12.9% stake in LogicBio (NASDAQ:LOGC), worth US$30mln, which is US$16mln more than Arix ploughed into the business.

READ: Arix Bioscience pours another £5.4mln into LogicBio as investee company lists on Nasdaq

The IPO, meanwhile, brought in gross proceeds of US$80.5mln and valued LogicBio at just over US$200mln at US$10 a share.

Founded four years ago and based in Cambridge, Massachusetts, the research and development group has licensed technology from Stanford and Texas universities that allows the insertion of corrective genes to the human genome.

It’s hoped the advance will allow LogicBio to create treatments for rare diseases with the company focusing initially on liver disorders in children.

Quick facts: Arix Bioscience PLC

Price: £1.16

Market: LSE
Market Cap: £157.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read